Clinical trials: Recurrent Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma With Sarcomatoid Features
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00068393
- Testing
- Doxorubicin, Gemcitabine, G-CSF (granulocyte-colony stimulating factor)
- Where
- 92 sites in United States
- Volunteers
- 39 people
- Sponsor
- Eastern Cooperative Oncology Group
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate, pembrolizumab, nivolumab, and atezolizumab in treating patients with melanoma, lung cancer, or kidney cancer…
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT03050060
- Testing
- Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Kidney Cancer
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00459875
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Wilms Tumor, Fibrosarcoma
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
- Conditions
- Wilms Tumor, Fibrosarcoma, Carcinoma, Round Cell, Nasopharyngeal Cancer
- Trial name
- NCT00141765
- Testing
- Myeloablative Chemotherapy, Stem Cell Rescue
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating children who have advanced…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00024258
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Kidney Cancer
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Gefitinib may stop the growth of kidney cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00467077
- Testing
- PEG-interferon alfa-2b, gefitinib
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- California Cancer Consortium
Kidney Cancer
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney…
- Trial name
- NCT00403169
- Testing
- lenalidomide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Adenocarcinoma of the Bladder, Distal Urethral Cancer
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
This phase II trial is studying how well sorafenib works in treating patients with progressive regional or metastatic cancer of the urothelium.
- Conditions
- Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer
- Trial name
- NCT00112905
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
This phase I/II trial is studying the side effects and best dose of isotretinoin when given together with vorinostat and to see how well they work in treating patients with advanced kidney cancer.
- Conditions
- Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00324740
- Testing
- vorinostat, isotretinoin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with bevacizumab and to see how well they work in treating patients with unresectable or metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00324870
- Testing
- vorinostat, bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Skin Carcinoma
Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
Solid organ transplant recipients (SOTR) have a 3-5x increased occurrence of cancer in contrast to the general population with basal and squamous cell skin cancer.
- Trial name
- NCT01764607
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
Kidney Cancer
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00089102
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Medical University of South Carolina
Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back.
- Conditions
- Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma
- Trial name
- NCT00749892
- Testing
- Erlotinib Hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Renal Carcinoma
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients.
- Trial name
- ATLAS (NCT01599754)
- Testing
- Axitinib
- Where
- 106 sites in United States, China and 7 more
- Volunteers
- 724 people
- Sponsor
- SFJ Pharma Ltd. II
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
This phase II trial is studying how well tandutinib works in treating patients who have undergone surgery for metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00408902
- Testing
- tandutinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
The purpose of this study is to find out what effects pazopanib (pazopanib hydrochloride) (also called Votrient®) may have on MRI (magnetic resonance imaging) scans, blood pressure, and various proteins in the blood.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01599832
- Testing
- pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00022633
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 92 sites in United States
- Volunteers
- 65 people
- Sponsor
- SWOG Cancer Research Network